4 news items
Guardant Health Launches New Guardant360 TissueNext Test With Nearly 500 Biomarkers To Identify More Treatment Options For Patients With Advanced Cancer
GH
4 Jun 24
strategies that are most effective for patients with advanced cancer. In addition to the panel expansion, Guardant has improved the test's operational workflow for a faster turnaround time.
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
GH
4 Jun 24
the targeted therapies or treatment strategies that are most effective for patients with advanced cancer. In addition to the panel expansion, Guardant has
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
GH
23 May 24
Clinical Trial of Competing Strategies. Arch Intern Med. 2012;172(7):575-582.
9. Doubeni, CA, et al. Modifiable
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
GH
3 Apr 24
heterogeneity, disease progression and treatment response. The epigenomic insights enable more personalized treatment strategies by increasing
- Prev
- 1
- Next